Group 1 - The core point of the article is that Xianruida Medical-B (06669) has received registration approval for its micro-guide wire from the Beijing Drug Administration, leading to a significant increase in its stock price [1] - As of the report, Xianruida Medical's stock rose over 12%, with a current price of 12.11 HKD and a trading volume of 18.9 million HKD [1] - The company plans to conduct marketing activities in China following the approval of the micro-guide wire, which is intended for routine peripheral vascular use [1] Group 2 - In December 2022, Xianruida Medical announced that Boston Scientific made a takeover offer to acquire up to 65% of the company's shares at a price of 20 HKD per share, with an estimated transaction value of approximately 523 million USD [1] - In July 2023, both companies signed a cooperation framework agreement and a service framework agreement to collaborate in areas such as global commercialization, manufacturing services, and product development [1]
港股异动 先瑞达医疗-B(06669)午后涨超12% 微导丝注册申请获批 公司和波士顿科学深度战略合作